Open Access

Jeremy de Beer, Chidi Oguamanam et Tobias Schonwetter Date de publication : septembre 2017 Télécharger : Chapitre 1: Innovation, propriété intellectuelle et développement en Afrique (3.7MB) ...

By Victor Nzomo In the midst of two decades of TRIPS and three decades of openness, more than 400 delegates from over 50 countries converged...

Authored by: Jeremy de Beer Abstract: Governments have long been interested in making intellectual property (IP) policy based on sound evidence. There is a large...

By Helen Chuma-Okoro and Nicole Tumaine This is part two of Helen Chuma-Okoro and Nicole Tumaine’s blog post on the insights retained from 2018 conferences,...

Par Abdelhamid Benhmade Sans pour autant être d’un optimisme béat ni sombrer dans un pessimisme démesuré, il est clair que la dérogation aux droits de...

By Uchenna Felicia Ugwu Achieving global food security will require innovation. Processes like plant phenotyping and technologies like digital imaging are examples of innovation that...

Par Ahou Rachel KOUMI Ce blogpost est la deuxième partie d’une série de deux blogs sur les Journées de l’Innovation en Contexte Académique réalisées du 19...

To assist trade policymakers in the development of a framework, this paper explores IP issues, perspectives, and priorities related to both the CFTA and PAIPO. It suggests that process and substance issues are each important to create fair and balanced IP systems on the continent that stimulate innovation, growth, and competition.

Just last month, I had the opportunity to participate in the 13th WIPO-WTO Colloquium for Teachers of Intellectual Property held at World Intellectual Property Organization (WIPO) and World Trade Organization (WTO) headquarters in Geneva, Switzerland from 13 to 24 June, 2016. I am beyond thankful for this scholarship and enjoyed an intense two week programme, covering eighteen substantive topics touching on all areas of intellectual property (IP) law. There were thirty-nine experts from WIPO, WTO, WHO, UNFCCC, UPOV, NGOs ,and industry who took part in the Colloquium as speakers and I was among twenty-six participants selected from approximately 160 applicants from developing countries around the world.

Edited by: Chidi Oguamanam. When the oral history of a medicinal plant as a genetic resource is used to develop a blockbuster drug, how is the contribution of Indigenous Peoples recognized in research and commercialization? What other ethical, legal, and policy issues come into play? Is it accurate for countries to self-identify as users or providers of genetic resources?